The distribution of copper in Sprague-Dawley rats following a three month oral administration of 0,10 or 50mg/kg copper aspirinate has been investigated. Metal content was determined by ICP-AES in blood, brain, kidney, liver, lung, spleen, and dejection. The results show that treatment with copper aspirinate did not cause accumulation of copper in rats and excess ingested copper was excreted through feces.
Introduction
Since the first report by Prof. J.R.J. Sorenson that copper complexes of many ligands had anti-inflammatory activity [1] ,copper aspirinate[Cu(ASA)],the copper complex of aspirin, has been found to be much more effective as an anti-thrombotic agent [] Data presented in Table 6 show that copper concentration in feces of treated animals, particularly with a dose of 50 mg/kg, was much higher than that of non-treated animals,which suggests that excess copper intake was excreted via feces. Bile may serve as the major excretory vehicle. The projected human dose of copper aspirinate is 2 mg/kg daily with a decrease to some maintenance dose with remission [7] . The 50 mg/kg dose used in these studies is 25 times the projected therapeutic dose but does not cause accumulation of copper. We conclude that copper aspirinate is safe for clinical use.
